MS and Demyelinating Disorders

Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.

Data from a pair of posters suggest that cognition, fatigue, and depression all impact social activity limitations in people with MS, rather than walking impairment alone.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.

Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.

The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.

The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.

The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.

The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.

The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.

Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.

Ahead of sessions kicking off on February 25, the ACTRIMS committee offered a look into what data, plenary talks, and developments are set to be presented at the upcoming ACTRIMS Forum 2021.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.

Siponimod (Mayzent; Novartis) improved Symbol Digit Modalities Test scores in patients at 12, 18, and 24 months compared to placebo.

Here's what is coming soon to NeurologyLive.

Big data is on the precipice of revolutionizing multiple sclerosis knowledge and treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

Researchers also found that patients treated with autologous hematopoietic stem cell transplantation had higher rates of infection then other DMT-treated groups.

The neurologist from Cleveland Clinic discussed how patients with early-onset NMOSD were more likely to have severe residual vision loss.

Researchers observed statistically significant improvements of the EDSS score along with a majority of patients showing no new enlarging or gadolinium-enhancing MRI lesions.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 12, 2021.

The treatment can be used in children who do not respond well to anticholinergic medications.

The neurologist from Cleveland Clinic discussed how her study reinforced previous findings that individuals with early onset neuromyelitis optica spectrum disorders are more likely to experience severe vision loss.

While patients with relapsing-remitting MS were found to benefit more from aHSCT, patients with progressive MS still experienced stability in disability scores.

Here's what is coming soon to NeurologyLive.